Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | KCNA5 | P22460 | 8/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.64 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19859245 | 1.00 | SLC6A4 (0.65) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Hydrochloric Acid SCHEMBL28712449 | 0.99 | KCNA5 (0.66) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL14288315 | 0.80 | KCNA5 (0.69) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL2624909 | 0.80 | KCNA5 (0.69) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL10207918 | 0.80 | KCNA5 (0.69) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL2624908 | 0.80 | KCNA5 (0.69) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL14535354 | 0.80 | KCNA5 (0.69) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL12810195 | 0.79 | SLC6A4 (0.56) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL2624907 | 0.79 | SLC6A4 (0.56) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL10266911 | 0.79 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10888552-B2 | Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability | Rothman, Steven (US) | 2021-01-12 | — | — | US | claimed |
| US-20190192493-A1 | TREATMENT OF DISORDERS OF SEXUAL AROUSAL WITH LOCAL APPLICATION OF AGENTS THAT INCREASE MEMBRANE EXCITABILITY | ROTHMAN STEVEN (US) | 2019-06-27 | — | — | US | claimed |
| CN-114105847-A | Refining method of Vernakalant hydrochloride | 上海旭东海普药业有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-10888552-B2 | Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability | Rothman, Steven (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190192493-A1 | TREATMENT OF DISORDERS OF SEXUAL AROUSAL WITH LOCAL APPLICATION OF AGENTS THAT INCREASE MEMBRANE EXCITABILITY | ROTHMAN STEVEN (US) | 2019-06-27 | — | — | US | disclosed |
| EP-2414543-B1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | DECODE GENETICS EHF (IS) | 2016-10-12 | — | — | EP | disclosed |
| US-8795963-B2 | Genetic markers for risk management of atrial fibrillation and stroke | DECODE GENETICS EHF. (IS) | 2014-08-05 | — | — | US | disclosed |
| US-20120021989-A1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | DECODE GENETICS EHF. (IS) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192493-A1 | TREATMENT OF DISORDERS OF SEXUAL AROUSAL WITH LOCAL APPLICATION OF AGENTS THAT INCREASE MEMBRANE EXCITABILITY | GABRE, SLC18A2, SLC18A1 | SLC6A4 662/4885KCNA5 1203/4885SCN5A 1614/4885 |
| US-10888552-B2 | Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability | GABRE, SLC18A2, SLC18A1 | SLC6A4 662/4885KCNA5 1203/4885SCN5A 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.